Navigation Links
New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
Date:3/10/2008

PALO ALTO, Calif., March 10 /PRNewswire-FirstCall/ -- Varian, Inc. (Nasdaq: VARI) announced today its new XSens(TM) Dual Cold Probe. Designed for use with the Varian NMR System, the new probe is Varian's most sensitive probe for 13C detected NMR experiments.

The XSens Probe offers productivity and data quality enhancements for researchers in pharmaceutical, agricultural, chemical and academic laboratories involved in the characterization of quantity-limited samples of natural products, reaction intermediates, metabolites and trace contaminants.

The new probe dramatically increases 13C sensitivity and reduces acquisition time 100-fold compared to a room temperature (RT) Dual Broadband (DB) probe. It also offers a significantly improved 1H sensitivity, reducing acquisition time for 1H detected experiments 75-fold compared to a RT DB probe. In addition to increasing throughput, the enhanced sensitivity for 13C makes it easier for researchers to take advantage of the simpler spectral information available from 13C experiments.

"The XSens Probe is a significant advance in Cold Probe technology," said Martin O'Donoghue, Senior Vice President, Scientific Instruments, Varian, Inc. "By greatly reducing acquisition times, this probe makes previously time- consuming 13C detected NMR analyses a more practical tool for busy laboratories."

For more technical information about Varian's NMR instrumentation, please visit http://www.varianinc.com/products/

Varian, Inc. is a leading worldwide supplier of scientific instruments and vacuum technologies for life science and industrial applications. The company provides complete solutions, including instruments, vacuum products, laboratory consumable supplies, software, training and support through its global distribution and support systems. Varian, Inc. employs approximately 3,900 people worldwide and operates manufacturing facilities in North America, Europe and Asia Pacific. Varian, Inc. had fiscal year 2007 sales of $921 million, and its common stock is traded on the NASDAQ Global Select Market under the symbol, "VARI." Further information is available on the company's Web site: http://www.varianinc.com.


'/>"/>
SOURCE Varian, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
2. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
3. Carl Hull Named President and Chief Operating Officer of Gen-Probe
4. Cascade Microtech Introduces Worlds First 45 nm-capable DC/RF Parametric Probe Card Solutions, Lowers Cost of Ownership
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
7. Gen-Probe to Webcast Three Upcoming Presentations
8. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
9. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
10. New FTMS System From Varian, Inc. Offers Switchable LC and GC Sources and True Triple Quadrupole Capabilities
11. New Chromatography Detectors From Varian, Inc. Extend the Range of Universal Detection for HPLC and LC/MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
(Date:3/23/2017)... , March 23, 2017 According to ... products and derivatives market is fragmented due to the presence of a ... as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each ... three companies, collectively, held more than 76% of this market in ... As of ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... closer look at four equities in the Biotech industry: ... EYEG), Synthetic Biologics Inc. (NYSE MKT: SYN), and Regulus ... March 21 st , 2017, Credit Suisse upgraded its rating ... stocks by downloading their free report at: ...
Breaking Biology Technology:
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... ...
(Date:3/7/2017)... , March 7, 2017   HireVue , ... top global companies identify the best talent, faster, today ... Chief Sales Officer (CSO) and Diana Kucer ... round out a seasoned executive team poised to drive continued ... building on a year of record bookings in 2017. ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
Breaking Biology News(10 mins):